-
CStone's PD-L1 antibody non-small cell lung cancer global phase 3 clinical registration reaches the primary endpoint
Time of Update: 2021-06-01
According to the press release, the primary endpoint is a multi-center, randomized, double-blind phase 3 clinical trial called GEMSTONE-301, which aims to evaluate sugarizumab as a consolidation therapy in concurrent or sequential radiotherapy and chemotherapy Efficacy and safety in locally advanced/unresectable stage III non-small cell lung cancer patients without disease progression afterwards.
-
up to date!
Time of Update: 2021-06-01
On May 26, the State Food and Drug Administration issued an announcement on protected varieties of traditional Chinese medicines.
will continue to be given 2 Level of protection, the protection period and the number of protected varieties are respectively May 06, 2021-May 9, 2027, ZYB20720200101.
-
Zvezumab inhibits IL-6 and significantly reduces the risk of atherosclerosis in high-risk patients
Time of Update: 2021-06-01
Adverse reactionsIn short, studies have shown that Zevezumab can significantly reduce inflammation and thrombosis associated with atherosclerosis.
Let us hope that the drug can benefit the majority of patients with atherosclerosis.
-
Sialon Pharmaceuticals: The company's omeprazole sodium for injection passed the consistency evaluation of generic drugs
Time of Update: 2021-06-01
The main indication for omeprazole sodium for injection that passed the generic drug consistency evaluation this time is for the treatment of acute upper gastrointestinal bleeding caused by duodenal ulcer, gastric ulcer, acute gastric mucosal lesions, and compound ulcers.
-
The second 1 billion Chinese patent medicine plaster was born!
Time of Update: 2021-06-01
The second 1 billion Chinese patent medicine plaster was born Sales of Yunnan Baiyao Ointment in Public Medical Institutions in China in Recent Years Source: Terminal competition landscape of China's public medical institutions Yunnan Baiyao Ointment is an exclusive product of Yunnan Baiyao, which is used for bruises, blood stasis, swelling pain, and rheumatic pain.
-
Chinese researchers have invented a gene editing technology for rape and cabbage that does not rely on genetic transformation
Time of Update: 2021-06-01
This method breaks the reliance on genetic transformation of rape and cabbage gene editing technology, edits the genes of rape and cabbage directly through pollination, and obtains mutant materials without genetically modified elements, which is a high-yield, high-quality, and multi-resistant new variety The cultivation provides new technical reserves.
-
Huadong Medicine's Class 1 new drug IMGN853 was approved for a pivotal single-arm clinical trial
Time of Update: 2021-06-01
The application for the first clinical trial of IMGN853 in China was approved on March 30, 2021, including the above-mentioned international multi-center phase III study and a phase I study evaluating safety, tolerability and pharmacokinetics in Chinese adult patients The criteria for patient entry included platinum-resistant advanced high-grade epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer patients with high expression of folate receptor alpha.
-
Hengrui Medicine's 5 anti-tumor studies are selected for Oral link
Time of Update: 2021-06-01
0 months of the placebo group; the median progression-free survival In terms of (PFS), the carrelizumab group was 6.
In terms of side effects, the incidence of ≥3 treatment-related adverse events (TRAEs) was 93% in the carrelizumab group and 90% in the placebo group.
-
Li Shuhong resigned as director of Jiangsu Haobo Biomedical and other positions
Time of Update: 2021-06-01
Li Shuhong resigned as a director, secretary of the board of directors and chief financial officer due to personal reasons, and the handover has been completed a few days ago.
-
Interim Measures of Zhejiang Province for Centralized Purchase of Pharmaceutical and Medical Consumables
Time of Update: 2021-06-01
Improve supporting policies such as quality supervision, production and supply, circulation and distribution, medical services, and medical insurance payments, strengthen departmental linkage, focus on reforming system integration, coordination and efficiency, and support and promote each other with the centralized procurement system.
-
Scientists find that mitochondrial enzymes can prevent iron death
Time of Update: 2021-06-01
Recently, a research team at the University of Texas Anderson Cancer Center discovered that the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) plays an important role in inhibiting iron death (ferroptosis).
-
Luye Pharma's innovative drug Liss' Mingdo Day transdermal patch obtained EU multi-country marketing authorization qualification
Time of Update: 2021-06-01
Luye Pharmaceutical Group announced that its self-developed innovative preparation, Liss’ Mindo Day transdermal patch, has successfully passed the EU decentralized review process.
-
Decitabine for injection passed the consistency evaluation of generic drugs
Time of Update: 2021-06-01
In 2008, it was approved to be imported and marketed in China for the treatment of myelodysplastic syndrome (MDS); in 2012, it was approved by the European Drug Administration for the treatment of elderly acute myeloid leukemia.
-
NASH treatment drug phase IIb study failed, stock price plummeted by 40%
Time of Update: 2021-06-01
Article source: Medical Rubik's Cube InfoOn May 24, NGM Biopharmaceuticals announced the data of a phase IIb clinical study code-named ALPINE 2/3, which aims to evaluate aldafermin in the treatment of non-alcoholic steatohepatitis (NASH) with stage 2 or stage 3 liver fibrosis (F2/ F3) Efficacy of patients.
-
Bayer's heart failure drug Verquvo is recommended by the EU CHMP and approved by China to enter the review
Time of Update: 2021-06-01
Data show that when used in combination with available heart failure drugs, compared with placebo, the once-daily 10 mg dose of vericiguat significantly reduces the relative risk of the composite endpoint of heart failure hospitalization and cardiovascular death after a worsening event by 10% (HR=0.
-
Haisco: IND application for new indications for HSK21542 injection has been accepted
Time of Update: 2021-06-01
HSK21542 injection (hereinafter referred to as "HSK21542") is a brand-new analgesic drug with independent intellectual property rights developed by Haisco.
According to my country's new chemical drug registration classification regulations, its drug registration is classified as chemical drugs.
-
Another pharmaceutical company stopped the science and technology innovation board
Time of Update: 2021-06-01
Recently, the Shanghai Stock Exchange issued an announcement stating that it would terminate the decision to review the initial public offering of shares of Suzhou Ruibo Biotechnology Co.
Regarding the Withdrawal of Initial Public Offering and Listing on the Sci-tech Innovation Board" and the "Application Documents" Guotai Junan Securities Co.
-
11 medicines are higher than the lowest prices in the five provinces and cities to withdraw from the Internet soon!
Time of Update: 2021-06-01
The price is higher than the lowest price in the five provinces and cities, and the companies involved include Jianlang Pharmaceutical, Jichuan Pharmaceutical, Wanle Pharmaceutical, Jinyuan Pharmaceutical, Baiyunshan Pharmaceutical General Factory, and Pfizer.
-
Type 1 diabetes antibody drug teplizumab is supported by the U.S. FDA Advisory Committee
Time of Update: 2021-06-01
In clinical trials supporting the drug NDA, a 2-week course of teplizumab treatment can delay the onset of type 1 diabetes by an average of 2 years.
-
"Millennium Medicine Capital" Hebei Anguo: 52.01 million yuan prize for outstanding private enterprises to encourage innovation and help growth
Time of Update: 2021-06-01
(Finish) Medical Network News on May 28th, 27th, Anguo City, Hebei Province held a private enterprise innovation and development conference.
(Finish) Medical Network News on May 28th, 27th, Anguo City, Hebei Province held a private enterprise innovation and development conference.
